COV
CLEO DIAGNOSTICS LTD
$0.3450
▼ -1.43%
Market cap
$49M
Turnover
$81,305
Last price
$0.3450
Day change
-1.43%
Announcements
13
Range, past year
Open 0.360 · Low 0.270 · Now 0.345 · High 0.900
Open COV in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
COV momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-10-13.
Momentum quality
37/100
Wyckoff phase
Accumulation8d
Trend stage
Emerging
1 Day
-1.4%
1 Week
-1.4%
1 Month
+3.0%
1 Year
-2.8%
RSI
55
Avg daily range
7.0%
CLEO DIAGNOSTICS LTD scores 37 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Emerging.
On the Wyckoff cycle it sits in Accumulation, where it has been for 8 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.
Against the wider market it is currently matching and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -30.0%
- High volatility (ATR 7.0%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
COV announcements
Recent price-sensitive releases.
- 2026-10-13 CLEO Commences Analytical Validation Ahead of FDA Submission Progress Report
- 2026-09-30 Cleo Files Patents for its Ovarian Cancer Screening Test Progress Report
- 2026-09-24 CLEO Commences Ovarian Cancer Screening Test Development Progress Report
- 2026-09-10 CLIA Certified Lab selected - Pivotal US Clinical Validation Progress Report
- 2026-09-03 CLEO Receives First Batch of Commercial Test Kits Progress Report
- 2026-08-20 Appendix 4E and 2026 Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-07-29 Quarterly activities and cashflow report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
More Health Care stocks
Most traded in the same sector.